BIA Separations brings ‘sense of urgency’ to Zolgensma agreement

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Krtichanut)
(Image: Getty/Krtichanut)

Related tags: SMA, BIA Separations, AveXis, Novartis, Catalent, Gene therapy, purification

AveXis and BIA Separations announce an agreement for the commercial purification process of SMA gene therapy drug Zolgensma and further gene therapy candidates.

Biochromatography development and manufacturing company, BIA Separations will work with AveXis for the commercial purification process of its newly approved gene therapy drug Zolgensma​ (onasemnogene abeparvovec-xioi) and the rest of its pipeline.

A BIA Separations spokesperson told us that it started working with AveXis, a Novartis company​, in other capacities several years ago, when it gaged the available technology for the purification of gene therapy products.

The treatment has been shown to halt disease progression in SMA patients and has become the first gene therapy for this treatment indication approved by the US Food and Drug Administration.

Zolgensma is a one-time infusion that provides a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression. If untreated SMA, a rare genetic disease, leads to progressive muscle weakness, paralysis, and can lead to permanent ventilation or death by age two.

BIA Separations will use its experience in viral and DNA purification for adeno-associated virus (AAV), and chromatographic technology for the purification and analysis of biomolecules as it supports AveXis’ gene therapy pipeline.

Andy Stober, SVP of technical operations for AveXis, stated that the work BIA has done in AAV purification and chromatographic technology were ‘important contributions’ in bringing gene therapies forward.

He added that BIA has shared and operated with “the same sense of urgency” ​as AveXis to “bring gene therapy to the SMA community.”

Catalent contributions

After the approval of Zolgensma, Catalent Biologics’ newly purchased subsidiary Paragon​ entered an agreement with AveXis as well. Per the agreement, Paragon will develop and manufacture Zolgensma in a dedicated production space at its commercial manufacturing center in Maryland, US.

Paragon will provide AveXis with access to Catalent’s AAV gene therapy development, manufacturing, and process characterization capabilities, and process development for clinical supply of any additional viral therapies in AveXis’ pipeline.

Additionally, Novartis entered an agreement with SAVSU Technologies​ to use the company’s cold chain shipment technology as AveXis’ pipeline develops.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...


Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Follow us


View more